Press Releases

YEAR
Toggle Summary Nabriva Therapeutics Provides Business Update and Announces Preliminary Financial Results for the Fourth Quarter of 2021
-SIVEXTRO ® (tedizolid phosphate) remains on track for return to historical peak sales by mid-2022- -XENLETA ® (lefamulin) Phase I Cystic Fibrosis (CF) trial on track to enroll first patient in Q122- -Cash resources of $47.7 million as of 12/31/21 provides cash runway well into Q422- DUBLIN,
View HTML
Toggle Summary Nabriva Therapeutics to Adjourn Extraordinary General Meeting of Shareholders on December 22, 2021
— Meeting to Reconvene on January 14, 2022 — DUBLIN, Ireland and FORT WASHINGTON, Pa. , Dec. 22, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious
View HTML
Toggle Summary Nabriva Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference
DUBLIN, Ireland and FORT WASHINGTON, Pa. , Dec. 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder ,
View HTML
Toggle Summary Lefamulin NDA Filed in Mainland China for Treatment of Community Acquired Pneumonia
DUBLIN, Ireland and FORT WASHINGTON, Pa. , Nov. 29, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that its partner,
View HTML
Toggle Summary Nabriva Announces Availability of XENLETA® (lefamulin) in a 10-Count Oral Pack
10-count oral pack – or ‘X’ pack allows for improved access and the opportunity to further expand retail availability DUBLIN, Ireland and FORT WASHINGTON, Pa. , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization
View HTML
Toggle Summary Nabriva Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update
-Revenues of $8.9 million increased 8% sequentially versus Q2 2021- -SIVEXTRO Net Sales & Prescriptions both grew 14% sequentially versus Q2 2021- -Cash runway extended to substantially through Q2 2022- -Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland , Nov.
View HTML
Toggle Summary Nabriva Therapeutics to Present at the Jefferies London Healthcare Conference
DUBLIN, Ireland and FORT WASHINGTON, Pa. , Nov. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder ,
View HTML
Toggle Summary Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Nov. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted a non-statutory stock option
View HTML
Toggle Summary Nabriva Therapeutics to Report Third Quarter 2021 Financial Results and Recent Corporate Highlights on November 9, 2021
DUBLIN, Ireland , Oct. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial
View HTML
Toggle Summary Nabriva Therapeutics to Present Data at CHEST Annual Meeting 2021
DUBLIN, Ireland and FORT WASHINGTON, Pa. , Oct. 15, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today, announced data presentation at
View HTML

For Media Inquiries

E-mail: PR@nabriva.com


For Investor Relations

E-mail: IR@nabriva.com